ARWR vs AXSM
Arrowhead Pharmaceuticals, Inc. and Axsome Therapeutics, Inc., both Healthcare
Axsome Therapeutics, Inc. is the larger company at $12B against $11B. Over the past year ARWR returned +105% against +45% for AXSM.
| Figure | ARWR | AXSM |
|---|---|---|
| Last close | $62.78 | $168 |
| Market cap | $11B | $12B |
| 1-year return | +105% | +45% |
| 5-year return | +0.4% | +544% |
| RyuScoresector-relative, 1–10 | 18/100 | 18/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Arrowhead Pharmaceuticals, Inc.
Revenue of $75M in Q3 2026, net income null.
Axsome Therapeutics, Inc.
Revenue of $218M in Q2 2026, net income null. Its largest reported line is Royalty And Milestone, 66% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.